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Kinesin family member 21b (kif21b) is one of the few multiple sclerosis (MS) risk genes with a presumed central
nervous system function. Kif21b belongs to the kinesin family, proteins involved in intracellular transport of proteins
and organelles. We hypothesised that kif21b is involved in the neurodegenerative component of MS and
Alzheimer’s (AD) disease. Post-mortem kinesin expression was assessed in 50 MS, 58 age and gender matched
non-demented controls (NDC) and 50 AD. Kif21b expression was five-fold increased in AD compared to MS and
NDC aged below 62 years (p = 8*10−5), three-fold between 62–72 years (p = 0.005) and not different above 72 years.
No significant differences were observed between MS and NDC. In AD, kif21b expression was two-fold increased in
Braak stage 6 (scoring for density of neurofibrillary tangles) compared with stage 5 (p = 0.003). In MS patients, kif21b
correlated with the extent of grey matter demyelination (Spearman’s rho = 0.31, p = 0.03). Abundant kif21b, defined
as expression above the median, was associated with a two-fold accelerated development of the Kurtzke Expanded
Disability Status Scale (EDSS) 6.0 (median time in low kif21b group 16 years vs. high kif21b 7.5 years, log-rank test
p = 0.04) in MS. Given the genetic association of kif21b with MS, the results were stratified according to rs12122721
[A] single nucleotide polymorphism (SNP). No association was found between kif21b expression or the time to EDSS
6 in kif21b risk SNP carriers compared to non-risk carriers. Kif21b was expressed in astrocytes in addition to neurons.
Upon astrocyte activation, kif21b increased nine-fold. Abundant kif21b expression is associated with severe MS and
AD pathology and with accelerated neurodegeneration independent of the kif21b risk SNP.
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Multiple sclerosis (MS) has classically been considered as
an auto-immune disease of the white matter. However,
the grey matter component of the pathology receives
increasing attention, especially because axonal and neuronal
degeneration occur already early in the disease [1]. This
area of research received an impulse by novel MRI
techniques to visualize grey matter lesions [2].
Recently, a large genome wide association study (GWAS)
in MS patients identified 57 single nucleotide polymorphisms
(SNP) associated with an increased risk to develop MS. Most
of the (SNP) have important functions in immune cells,
mainly in T-cell biology [3]. However, a few of these SNP* Correspondence: r.hintzen@erasmusmc.nl
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unless otherwise stated.may be involved in neurodegeneration. Kif21b is one
of these SNP, which was also associated with MS risk
in earlier studies [4].
Kif21b is a relatively poorly studied member of the
kinesin family, expressed most profoundly in the CNS,
especially in the dendrites of neurons [5]. The kinesin
superfamily contains 45 genes, known as kinesins or kifs,
which are divided into 15 different families. These kifs
are mainly expressed in neurons, and are localised in
axons and dendrites in the CNS. Members of the kinesin
family consist of a motor domain, a binding site for
microtubules, and a specific cargo binding domain for
the transport of different molecules and organelles.
Neuronal functioning and survival largely depend on
intracellular microtubule mediated transport, which is
especially well developed in neurons, because long
distances need to be covered along the axon [6]. The
exact function and cargo transported by kif21b ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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family members has been linked to neurodegenerative dis-
eases like amyotrophic lateral sclerosis (ALS), Huntington’s
and Alzheimer’s disease [7].
Dementia is characterized by memory loss, cognitive
impairments and decline in intellectual performance. The
majority of patients with dementia suffer from Alzheimer’s
disease (AD). Neuropathological changes include the extra-
cellular deposition of Aβ peptide in plaques, reactive gliosis
[8] and intraneuronal aggregation of hyperphosphorylated
Tau in tangles. Tau is a microtubule associated protein and
binds to tubulin [9], along which kinesins transport their
cargo. In AD, Tau is abnormally phosphorylated and
therefore dissociates from microtubuli [10], leading to
the formation of neurofibrillary tangles (NFT). The level
of NFT strongly correlates with neuronal dysfunction and
clinical progression in AD [11]. The extend of Tau
pathology is reflected in the Braak stage [12].
We hypothesized that kif21b is aberrantly expressed in
neurodegenerative disease and that its expression is
associated with disease progression. Therefore, kif21b
expression was assessed in 50 MS patients compared
with 58 non-demented controls (NDC) and with 50
Alzheimer’s patients (AD). We found that cortical kif21b
expression is significantly increased in AD patients
compared with MS patients and NDC, independently of
the MS risk genotype. Moreover, in AD and MS patients
with more severe neuropathology, significantly higher
expression levels of kif21b were found. This increased
kif21b expression was associated with a shorter disease
duration in both MS and AD patients and accelerated




Brain and spinal cord tissue was obtained from the
Netherlands Brain Bank (NBB), Netherlands Institute for
Neuroscience, Amsterdam. The cortical tissue consisted
of the medial temporal gyrus of 50 Alzheimer patients
(including two AD patients: superior frontal gyrus tissue),
50 multiple sclerosis patients (including six tissues of
MS patients from the superior frontal gyrus and one
hippocampus) and 58 age and gender matched non-
demented controls (all medial temporal gyrus). The majority
of non-demented controls were free of neurological disease.
However, three patients had cerebral or cerebellar microme-
tastases of carcinomas, one NDC had a small Schwannoma
of the right vestibulocochlear nerve four NDC had old
infarctions and one had mononeuropathy multiplex. None
of the tumours or infarctions were located in the tissues
sections studied here. White matter tissue was obtained
from 18 NDC, 23 MS and three AD patients. Additionally,
seven MS spinal cord samples were tested. The medicalethical committee of the Free University Medical Center
Amsterdam, The Netherlands, has approved this study and
all materials have been collected from donors from whom
written informed consent for brain autopsy and the use of
the material and clinical information for research purposes
had been obtained by the NBB. Brain tissue was stored
at −80°C until use.
RNA isolation and real-time quantitative PCR
For isolation of total RNA 5–7 cryo-sections of 50 μm
were used. RNA isolation was performed by using the
GenElute Mammalian Total RNA Miniprep Kit (Sigma).
RNA samples were treated with DNAse I to remove
contaminating DNA (Invitrogen). Using 1.0 μg RNA as a
template, copy DNA (cDNA) was reverse transcribed by
using Superscript II (Invitrogen). Primers and probes
were selected by using the Universal ProbeLibrary Assay
Design Centre (Roche). To determine target gene mRNA
expression, real-time quantitative reverse transcription
PCR was performed using TaqMan technology. GAPDH
mRNA and GUSB (for brain tissue) or 18S (for astrocyte
cultures) RNA levels were measured as a control to
normalize for RNA input. Both GUSB and 18S validated
the GAPDH results. Reference gene primers and probes
were obtained from Applied Biosystems. An Applied
Biosystems 7900 Sequence Detector was programmed
for the initial step of 2 min at 50°C and 10 min at 95°C,
followed by 40 thermal cycles of 15 s at 95°C and 1 min
at 60°C. For calculation of mRNA expression levels, Ct
values per gene were applied to standard curves, generated
for each gene of interest. Sequences of the primers are
listed in Additional file 1: Table S1a.
DNA isolation from brain tissue
5–10 mg of brain tissue was lysed using cell lysis solution
(Qiagen) and Proteinase K (MP Biomedicals LLC) was
added and incubated at 55°C over night. Samples were
treated with RNAse A solution (Qiagen) and incubated at
37°C for 1 h. Protein precipitation solution (Qiagen) was
added, and the samples were placed on ice for 5 min.
100% isopropanol was added to the supernatant and DNA
was precipitated with 70% ethanol and hydrated in Tris
EDTA buffer (TE-buffer) at 55°C for 5 min and stored at
4°C for SNP detection.
SNP detection in brain tissue
Risk SNP carriership of rs12122721 [A] in brain tissue was
assessed in order to analyze whether this corresponds with
mRNA expression levels. SNP detection was performed
using Taqman assay (Applied Biosystems) as previously
described [13]. NDC, MS and AD donors were all in
Hardy Weinberg equilibrium (p = 0.72) and the call rate
was 98.9%.
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Immunohistochemistry was performed on frozen sections
of brain tissue to detect kif21b protein. Briefly, 6 μm frozen
sections were cut and thawed onto gelatine-chrome alum
coated glass slides. Slides were kept overnight at room
temperature in humidified atmosphere and air-dried for
1 h. Thereafter, slides were fixed in acetone containing
0.02% (v/v) H2O2. Slides were then air-dried for 10 min,
washed with PBS and incubated with optimally diluted
primary antibody specific for kif21b. Incubation with
secondary antibody was performed, followed by tyramide
signal amplification (TSA) according to the manufacturers’
protocol (Invitrogen). HRP activity was revealed by incuba-
tion for 10 min at RT with 3-amino-9-ethyl-carbazole
(AEC, Sigma) substrate, leading to a bright red precipitate.
Slides were embedded with glycerol-gelatin (Boom).
Incubation with isotype control antibodies of irrelevant
specificity and omission of primary antibody were used as
negative controls.
Grey matter lesion staging
MS grey matter brain lesions were staged on the basis of
demyelination criteria, as described earlier [14]. Grey
matter tissue was stained with monoclonal antibodies
against PLP, NeuN and MAP2 using immunohistochemical
detection. The slices were scanned using a Nanozoomer
microscope (Hamamatsu). Lesions were digitally staged
according to the classification scheme for grey matter
demyelinating lesions, using the Nanozoomer Digital
Pathology software version 1.2. Shortly, lesions were
scored as mixed white-grey matter (Type I), intracortical
(Type II), subpial (Type III) and lesions stretching from the
pia mater until the border of white matter (Type IV). Two
independent observers (KLK, MvM), blinded to clinical
information and kif21b expression, scored grey matter
lesions based on PLP staining, on a standardized scoring
form. Morphometric information regarding total area of
the slide, area containing white matter in the tissue (based
on absence of MAP2 and NeuN expression), total number,
types and area of grey matter lesions was assessed.
Moreover, expression of HLA-II was scored as well as
meningeal infiltration. In addition, when the slide
contained white matter lesions, the area and HLA-II
expression of these lesions was scored.
Staging of MS white matter lesions
MS brain lesions were staged based on internationally
accepted criteria for inflammation and demyelination as
described earlier [15,16]. We used three different
markers, i.e. acid phosphatase, HLA-DP,DQ,DR and
neutral lipids. To detect infiltrating myeloid cells, we
stained acid phosphatase (lysosomal enzyme). Activated
cells can be detected with an antibody against HLA-DP,
DQ,DR. Myelin breakdown products, reflecting activedemyelination, were detected with oil-red O (marker for
neutral lipids).
Immunofluorescence
Double-labelling of kif21b expressing cells with NeuN,
MAP-2, HLA-II or CD68 was performed using immuno-
fluorescence as described previously [17]. Sections were
first incubated with primary antibody mixture for 1 h,
followed by incubation of a mixture of secondary
antibodies for 30 min. Sections were mounted in
Prolong Gold (Molecular Probes) with 80 ng/ml DAPI
(Molecular Probes).
Confocal fluorescence images were obtained on a
Leica SP5 confocal system (Leica Microsystems CMS
GmbH), equipped with an Argon laser (488 nm), Diode
lasers (405 nm) and HeNe laser (633 nm). Images were
taken using a 63x NA 1.4 objective. Images were recorded
using standard Las-AF software version 2.6.3 (Leica
Microsystems CMS GmbH). Possible crosstalk between
the different fluorochromes, which could give rise to
false-positive co-localization of the signals, was completely
avoided by careful selection of the imaging conditions.
Emission windows for Alexa Fluor 488 dyes were between
498-578 nm and for Alexa Fluor 647 between 643-775 nm,
and Kalman averaging was used.
All antibodies used in this study are indicated in
Additional file 1: Table S1b.
Astrocytoma cell line cultures
U251MG human astrocytoma cells (ECACC 89081403,
passage 28) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with GlutaMAX/Ham’s F-10 Nutrient
Mix 1:1 containing 10% fetal bovine serum (FBS), 10
U/ml penicillin G and 10 mg/ml streptomycin (1% P/S)
(all Invitrogen) at 37°C/5% CO2.
Primary human astrocyte isolation and culture
For primary human adult astrocyte cultures, we obtained
freshly dissected post-mortem subcortical white matter
from a 79-year-old female control with a post-mortem
delay of <18 hours (h) and a pH of the cerebrospinal
fluid of 6.30 from the NBB. The tissue was collected in
25 ml cold Hibernate A (Invitrogen), and mechanically
dissociated into small pieces. The tissue was digested with
0.2% trypsin (Invitrogen) and 0.1% DNAse I (Invitrogen)
at 37°C, while shaking for 30 min. Next, 2 ml FBS was
added to the mixture and, subsequently, the cells were
collected by centrifugation. The pellet was taken up in
DMEM without phenol red containing 10% FBS, 2.5%
Hepes, and 1% P/S (all Invitrogen), and the suspension
was filtered through a 60 μm mesh screen. Then, Percoll
(Amersham/GE Healthcare) was added (half of cell
suspension volume), and this mixture was centrifuged
to separate cells, debris and myelin at 3220 relative
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layer (glial cell containing fraction) was collected and
washed with complete DMEM (containing 10% FBS,
1% P/S, 2.5% Hepes and 1% gentamycin, all Invitrogen).
After centrifugation, the pellet was taken up in complete
DMEM and cells were seeded in a 6-cm uncoated culture
dish. Microglia will adhere to the dish and the astrocytes
will be present in the medium. After 6 h at 37°C/5%
CO2, the medium, containing astrocytes, was taken off,
centrifuged, and the microglia depleted pellet was seeded
onto poly-L-lysine coated wells (PLL, Sigma-Aldrich,
15 μg/ml in PBS, 1 h at room temperature) in DMEM/
Ham’s F12 GlutaMAX medium containing 5% FBS and
1% P/S (all Invitrogen).
Cytokine treatment in astrocytic cultures
U251MG astrocytoma cells or primary human astrocytes
were plated in 24-well plates (25.000 cells per well) in their
respective culture medium and allowed to adhere overnight.
Then, medium was replaced and cells were cultured in
medium with vehicle (PBS) or medium with a combination
of recombinant human IFN-γ (R&D systems, 50 ng/ml) and
recombinant human IL-1β (R&D systems, 50 ng/ml). After
48 h, cells were collected for mRNA isolation.
Statistical analysis
Gene expression data and presence of the SNP compared
to kif21b expression levels were analyzed using Kruskal
Wallis test for multiple groups. For subgroup comparisons,
Dunn’s Multiple Comparisons test was used. Mann
Whitney U-test was performed to test differences between
two groups. To determine correlations, non-parametric
Spearman’s test was used. For survival analysis, the time
between onset of MS and reaching EDSS 6.0 [18] was
calculated and kif21b expression was dichotomized with
expression above and below the median. Kaplan-Meier
curves were constructed and differences in time to
reach EDSS 6.0 were tested with a log-rank test. Hazard
regression was performed to correct survival data forTable 1 Clinical and demographical data
NDC (n = 58)
Age at death (SD) 71 (13)
Median post-mortem delay in hours (IQR) 7:35 (6:18–9:16)
pH (IQR) 6.64 (6.45-6.94)
Percentage female 72





IQR: interquartile range.confounding variables. Statistical analysis was performed
using SPSS version 20 (IBM). Graphs were made in
GraphPad Prism and Dunn’s multiple comparisons test
were also performed in GraphPad Prim version 5.04
(GraphPad Software Inc.). p-values <0.05 were considered
statistically significant and are denoted in the figures
as *p < 0.05, **p < 0.01 and ***p < 0.001.
Results
Characteristics of AD and MS patients and NDC
We assessed the size of the investigated tissue and
the percentage of grey matter in the tissues of MS,
AD and NDC and these characteristics were similar
(Additional file 1: Figure S1). No significant differences in
kif21b expression were found between tissues obtained
from the medial temporal gyrus or the superior frontal
gyrus (Additional file 1: Figure S2). The age at death, pH of
the CSF, and post-mortem delay (PMD) were significantly
different between NDC, MS and AD (Table 1). Linear
regression showed no clear trend for kinesin expres-
sion and PMD or pH, in contrast to age at death
(Additional file 1: Table S2). Thus, for disease specific
kinesin expression, stratification according to age at death
was performed based on the age quartiles of NDC.
Kif21b is increased in AD patients compared with MS
and NDC
During physiological aging in NDC, no changes in
kif21b expression were observed with increasing age
(p = 0.9, Figure 1A). However, a significant decrease of
kif21b over age was observed in MS (p = 0.03, Figure 1B)
and AD patients (p = 5*10−4, Figure 1C). Comparing MS,
AD and NDC in the different age groups, we found that
kif21b is significantly increased in AD compared with MS
patients and NDC. Interestingly, in the age category below
62 years of age, an approximately five-fold increase in
kif21b was observed in AD patients compared with MS.
Kif21b in AD compared to NDC was approximately
six-fold increased (p = 9*10−5), whereas no significantMS (n = 50) AD (n = 50) p-value
63 (13) 66 (9) 0.004
6:57 (5:25–8:15) 5:20 (4:27–6:13) 4*10−7
6.50 (6.36-6.71) 6.47 (6.34-6.67) 0.02
74 76 0.92
31 (62.0) 21 (42.0%) 0.24
15 (30.0) 26 (52.0%)
4 (8.0%) 3 (6.0%)
0 (0) 0 (0)
Figure 1 Kif21b expression in the grey matter does not change during physiological ageing, but is significantly increased in young
Alzheimer patients. Kif21b expression was stratified according to the age at death into three categories based on age at death of the NDC
(<25th percentile represents <62 yrs, between 25-75th percentile equals 62–72 yrs or >75th percentile is >72 yrs). Kif21b was compared between
the three age categories in A) NDC, B) MS and C) AD.
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age group from 62–72 years, a three-fold increase in
AD compared with MS and two-fold between AD and
NDC (p = 0.005) was observed. In the elderly patients
(>72 years), no differences between MS, AD and NDC
were found (p = 0.23, Figure 2A). Next, we assessed
whether the alterations in kif21b expression might reflect
differences in neuron density. Therefore, we used
NeuN (RBFOX3) as marker for neuron density and
found a significant reduction in NeuN in the AD patients
compared with NDC above 72 years of age (p = 0.006,
Figure 2B), whereas no differences between these
groups in kif21b expression were found (Figure 2A).
Additionally, we determined the expression of other
CNS specific markers, GFAP (astrocytes) and MBP
(oligodendrocytes). In the youngest AD, we observed
a significant increase of GFAP (p = 0.02) compared
with MS and in MBP (p = 0.003) compared with NDC
and MS (Additional file 1: Figure S3). No significant
differences between males and females were observed orFigure 2 Cortical kif21b is significantly increased in younger Alzheimer
significantly increased in AD patients younger than 62 years at death compar
62–72 yrs compared with MS patients in the same age category. B) No signifi
marker, in the youngest two age categories. However, NeuN expression signibetween primary progressive and secondary progressive
MS (Additional file 1: Figures S4 and S5 respectively).
Additionally, we validated kif21b expression levels cor-
rected for PMD as there were slight, though significant
differences in PMD between the different patients groups.
Similar results were found for kif21b expression corrected
for PMD as with the uncorrected kif21b expression, indi-
cating that it is unlikely that the PMD has influenced the
kif21b expression (Additional file 1: Figure S6).
Kif21b in spinal cord correlates with cortical kif21b
expression of MS patients
The medial temporal gyrus is preferentially affected in
AD, while this area is affected in approximately 34% of
clinically isolated syndrome patients (CIS, the first attack
of neurological deterioration in MS) [1]. To investigate
whether kif21b levels in a commonly affected area in MS
correlates with expression in the temporal gyrus, we
assessed kif21b expression in seven matched brain
and spinal cord tissues. We found a clear trend betweenpatients compared with MS and NDC. A) Kif21b expression is
ed with MS and NDC younger than 62 yrs and in AD patients between
cant differences were found in the expression of NeuN, a neuron specific
ficantly decreased in elderly AD patients compared with NDC.
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(p = 0.06, Additional file 1: Figure S7).
No correlation between increased kif21b expression and
kif21b risk SNP
We hypothesised that kif21b expression is influenced by
the kif21b risk SNP and therefore kif21b expression was
stratified according to rs12122721 [A] risk allele carriership
in the three patients groups. In none of the three
groups, carriership of the risk allele correlated with
kif21b expression (all p > 0.54, Figure 3A). Even after
pooling all donors for the three groups, no difference
in kif21b expression between the different genotypes
was found (p = 0.74, Figure 3B).
More severe pathology is associated with increased
kif21b expression in AD and MS
Next, we hypothesised that kif21b expression correlates
with the severity of neuropathology in Alzheimer and
MS. AD pathology was staged according to the Braak
criteria [12] by experienced neuropathologists from the
Netherlands Brain Bank. Kif21b mRNA expression was
stratified according to these criteria. Kif21b expression is
significantly higher in Braak stage 6 compared with
Braak stage 5 (p = 0.003, Figure 4A). Additionally, we
assessed whether the level of kif21b expression correlated
with the extent of grey matter demyelination in MS
patients. A significant correlation between kif21b and
the percentage of cortical demyelination was found
(Spearman’s rho = 0.31, p = 0.03, Figure 4B), indicating
that kif21b is increased with more severe neuropathology.
Kif21b is approximately ten-fold more abundant in MS
white matter compared to NDC
In view of the significant correlation between the amount
of grey matter demyelination and kif21b expression, weFigure 3 No differences between MS risk genotypes and kif21b expre
AD and stratified according to kif21b rs12122721 [A] risk genotype and wit
between the risk genotypes or diseases were observed. B) The three group
according to the rs12122721 genotypes. No significant differences were obhypothesised that kif21b is increased in the white matter
(WM) of MS patients, a common area of demyelination in
MS. Kif21b mRNA expression was assessed in the white
matter of 11 NDC and 16 MS patients (Additional file 1:
Table S3) and we found that kif21b was approximately
ten-fold increased in MS compared with NDC (median
and IQR of kif21b expression relative to GAPDH in NDC
0.037, 0.006-0.34 vs. MS 0.36, 0.17-0.34, p = 0.03, Figure 5).
Comparing the levels of expression between the white
and grey matter in NDC revealed that kif21b is highly
expressed in the grey matter and hardly in the WM
as expected with a kinesin highly enriched in den-
drites of neurons. Interestingly, in MS patients the
levels of expression in the WM and GM are comparable
(Figure 5). Both GFAP and MBP were increased in
MS patients (Additional file 1: Figure S8).
Kif21b protein is increased in AD patients and expressed
in neurons and astrocytes
Using immunohistochemistry, we next assessed whether
kif21b protein is also increased in the cortex of AD pa-
tients compared with NDC and MS (Additional file 1:
Table S3) to validate our mRNA findings in grey matter
tissues. Firstly, we assessed which cell types expressed
kif21b. Both glia cells and neurons expressed kif21b
(Figure 6A). Next, we semi-quantitatively scored kif21b
expression in age-, gender- and genotype matched NDC,
MS and AD patients. Kif21b expression was higher in AD
patients compared with MS and NDC, both in neurons
and in glia cells (Table 2), confirming the mRNA data
(Figure 2). Next, we assessed whether the kif21b protein
was also expressed in the white matter. In one NDC out
of 16, we could not detect any kif21b protein in the white
matter, in three out of 14 MS patients kif21b protein was
not observed in the WM (Figure 6B). In the WM of three
AD patients, we also observed kif21b protein expression.ssion levels. A) Kif21b expression was compared within NDC, MS and
hin genotypes between the different diseases. No obvious differences
s of donors were pooled and kif21b expression was stratified
served between the three genotypes.
Figure 4 Kif21b expression correlates with both AD and MS pathology. A) Kif21b expression was stratified for AD patients according to the
Braak criteria. AD patients with more severe AD pathology (Braak stage 6) had significantly higher kif21b expression levels. B) For MS patients, the
total area of grey matter demyelination was quantified and percentage of cortical demyelination was calculated. With increasing percentage of
GM demyelination, enhanced kif21b expression was observed.
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individual tissues, some areas had very high kif21b expres-
sion, whereas other regions are completely kif21b negative
(Additional file 1: Table S4) and this hampers reliable quan-
tification. This variation possibly indicates that kif21b is
expressed in activated cells. Lastly, we assessed which cell
types expressed kif21b. No kif21b expression was found in
microglia cells (Additional file 1: Figure S9A and B) or in
SMI32 positive axons (Additional file 1: Figure S9C and D).
High kif21b expression was found as expected in neurons
(Figure 6C) and interestingly also in astrocytes (Figure 6D).
Only in young AD patients, GFAP mRNA correlated with
kif21b expression in the grey matter (Figure 6E, Additional
file 1: Figure S10). In frontotemporal dementia, especiallyFigure 5 In MS white matter, kif21b is approximately ten-fold
increased compared with NDC white matter. Kif21b expression in
the white matter of 16 MS and 11 NDC was determined. MS
patients had approximately ten-fold increased kif21b expression
compared with NDC (white bars). As a reference, the kif21b cortical
expression levels are shown (grey bars). In MS patients, kif21b white
matter expression equalled kif21b grey matter expression, whereas
in NDC kif21b expression in the white matter compared with the
grey matter was significantly lower.young patients have reactive astrocytosis [19], comparable
with our findings. Additionally, also in the white matter of
MS patients (Figure 6F), but not NDC (Figure 6G), a
positive correlation between GFAP and kif21b mRNA
expression was found, again pointing to activation of
astrocytes.
Kif21b is upregulated during astrocyte activation
Most knowledge on kifs focused on neurons and virtually
nothing is known regarding kinesins in astrocytes.
Therefore, we decided to determine kif21b in astrocytes
further. We asked whether astrocytes express a basal level
of kif21b or that the observed kif21b expression in both
WM and GM astrocytes reflects reactive astrocytosis. The
astrocytoma cell lines U251 was stimulated with IL-1β
and IFN-γ for 48 h and kif21b expression was compared
between unstimulated and stimulated conditions. The
activation status was determined by assessing IL-6
production (Additional file 1: Figure S11A and B). Upon
astrocyte activation, kif21b increased approximately
nine-fold (Figure 7A). To assess whether this is specific
for kif21b or that other kinesins are also induced
and therefore reflecting cell activation in general,
kif1bα and kif5a expression levels were also deter-
mined. The expression of kif1bα did not change dur-
ing astrocyte activation (Figure 7B), whereas kif5a
slightly decreased (Figure 7C). Lastly, we determined
whether this mechanism is also observed in primary
astrocytes isolated directly post-mortem, to corrobor-
ate the U251 study. Similar, but more pronounced
changes in kinesin expression upon activation were
observed (Figure 7D-F).
High levels of kif21b expression are associated with a
more rapid and severe disease course in MS and AD
Given the correlation between kif21b and neuropathology,
we hypothesised that kif21b expression contributes to
Figure 6 Kif21b is expressed in astrocytes and costains with GFAP in AD grey matter and MS white matter. Representative
immunohistochemical staining of kif21b expression in A) the grey matter (out of 25 investigated tissues, Table 2) and B) in the white matter
(out of 26 samples, Additional file 1: Table S4). Based on morphology, different cell types express kif21b. Immunofluorescence staining in six
tissues revealed that C) kif21b is expressed in the somata of neurons and D) kif21b is expressed in the cell body as well as the processes of
astrocytes. For both C and D, the left column is DAPI, the middle column kif21b and the right column the cell-type specific marker as indicated
in the merged figure. Kif21b expression correlates with GFAP expression E) in the young AD patients in the grey matter, F) in MS white matter,
G) no correlation was found between GFAP and kif21b in white matter of NDC.
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http://www.actaneurocomms.org/content/2/1/144more rapid progression in neurodegeneration. Therefore,
we assessed whether a correlation between disease
duration and kif21b expression existed. In AD, high
kif21b expression was associated with a significantly
shorter disease duration (Spearman’s rho −0.36, p = 0.02,
Figure 8A) and a similar trend was observed in MS
(Spearman’s rho −0.27, p = 0.067, Figure 8B). Next, we
assessed whether kif21b levels in MS also correlated with
a shorter time to reach EDSS 6.0, a measure for sustained
disability. Kif21b was dichotomised as expression above or
below the median and a Kaplan Meier survival curve was
constructed. Kif21b expression above the median is
associated with an approximately two-fold more rapidprogression to EDSS 6.0 compared to expression below
the median (Log Rank test, p = 0.04, Figure 8C). MS
patients with abundant kif21b expression had a three-fold
increased risk to have an accelerated disease course
(hazard ratio (HR) for abundant kif21b in the development
of sustained disability corrected for age at onset 3.0, 95%
CI 1.4-6.4, p = 0.003), independent of gender. Given the
significant correlation between kif21b and the percentage
of GM demyelination, we assessed whether the time to
develop EDSS 6.0 is independent of GM demyelination.
Abundant kif21b expression adjusted for the percentage of
GM demyelination revealed that a rapid progression to
EDSS 6.0 is independent of the percentage of GM
Table 2 Quantification of kif21b expression in situ






Neuropathology assessment Kif21b1 Kif21b
genotypeBraak stage Amyloid Neu-rons Glia cells
NDC2 49 F NA NA 0 ND + - GA
NDC4 53 F 0 0 +/− - GA
NDC6 56 F 0 0 +/− - GG
NDC8 62 F 1 0 +/− - GA
NDC10 70 F 0 B + + GA
NDC13 50 M 1 0 - - AA
NDC29 77 M 1 B +/− / + - GG
NDC30 78 M 1 A +/− +/− AA
NDC36 82 M 1 A +/− - GG
MS4 50 F Myelitis 7 ND ND - - GG
MS6 56 F ND 4* ND ND + + GG
MS8 63 F Optic neuritis 17 0 0 + - GA
MS10 70 F Cerebrum 30 1 0 - - GG
MS23 56 M Myelitis 2 ND ND - - AA
MS25 57 M Myelitis 6 ND ND +/− - GG
MS40 74 M Myelitis 8 3 0 - - AA
AD2 57 F NA NA 6 C + +/− GA
AD4 57 F 6 C + - GG
AD6 59 F 5 C +/++ +/++ GA
AD8 63 F 5 C +/− - GG
AD10 70 F 5 C + - GA
AD13 42 M 6 C +/− +/− AA
AD15 54 M 6 C + +/− AA
AD20 58 M 4 C ++ ++ GG
AD42 76 M 5 C + +/− GA
In age-, gender- and genotyped matched MS and AD patients, kif21b protein expression was assessed. NA not applicable, ND not determined or documented.
1scored as: − no positive cells, +/−1–2 positive cells per field, + maximum of ~30% of the cells positive, ++ ~60% of the cells positive, +++ ~80% positive cells
and +++ (virtually) all cells positive.
*time to EDSS 9.0.
Neuropathology assessment based on Braak criteria [12].
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http://www.actaneurocomms.org/content/2/1/144demyelination. Moreover, GM demyelination is not associ-
ated with the time to develop EDSS 6.0 (Additional file 1:
Table S5). No significant difference in time to reach EDSS
6.0 between kif21b risk SNP carriers and non-risk SNP car-
riers (p = 0.22, Figure 8D) was observed, indicating that the
accelerated neurodegeneration is independent of the
MS risk SNP (HR 1.3, 95% CI 0.61-2.79, p = 0.07).
Additionally, adding the kif21b risk SNP to the Haz-
ard regression model for the effect of abundant kif21b
expression on the time to develop EDSS 6.0 did not
alter the results, indicating that kif21b expression is
the explanatory factor (Additional file 1: Table S5). Given
the association between astrocyte activation and kif21b
expression, we assessed whether high expression of GFAP
correlated with an accelerated time to EDSS 6.0 and
found no association (HR 0.97, 0.45-2.07, p = 0.94).Thus, abundant kif21b expression is an independent
predictor for accelerated progression to develop EDSS
6.0 (Additional file 1: Table S5).
Other kinesins are not associated with accelerated
neurodegeneration
Lastly, we assessed whether abundant kinesin expres-
sion in general is associated with a more rapid neuro-
degeneration in MS. Therefore, we tested six other
kinesins of different kinesin families. Two of these
kinesins have previously been associated with MS
(kif1b and kif5a), although subsequent validation of
kif1b failed [20], whereas the other kinesins are unre-
lated to MS. Members of the kinesin-1 superfamily
(kif5a, b, c and the kinesin light chain, KLC) are associated
with AD. For kif5a specifically, we observed a trend that
Figure 7 Expression of kif21b, but not other kinesins increases upon astrocyte activation. The astrocytoma cell line U251 was stimulated
with IL-1β and IFN-γ for 48 h in three independent experiments in duplo. A) Kif21b expression increased approximately nine-fold upon stimulation,
whereas B) kif1bα did not change C) and kif5a slightly decreased. Next, primary isolated astrocytes of a NDC were also stimulated in one experiment in
triplo and similar changes in kinesin expression were found (D-F).
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http://www.actaneurocomms.org/content/2/1/144abundant expression is associated with a shorter time to
develop EDSS 6.0 (HR 2.0, 95% CI 0.97-4.2, p = 0.06).
None of the other kinesins showed a trend towards accel-
erated neurodegeneration (Additional file 1: Table S6), in-
dicating that specific kinesins are involved in a more rapid
disease course.
Discussion
Genetic variations in the kif21b locus confer a modestly
increased risk to develop MS [3]. However, the underlying
mechanisms are currently completely unknown. We here
show that abundant levels of kif21b are associated
with accelerated progression to EDSS 6.0 and a shorter
disease duration in MS. Similarly in AD, high levels of
kif21b expression are found in patients who have had a
short disease duration. Moreover, increased levels of
kif21b are associated with more severe neuropathology in
both AD and MS. The observed differences in expression
and progression were independent of the MS risk
SNP. Similar to our findings, Harding et al. found no
association between the kif21b SNP and the time to
develop EDSS 6.0 [21]. We and others have functionally
investigated the intronic rs12122721 [A] SNP, whereas
recently the rs7522462 [G] SNP was reported in the
largest MS GWAS. Rs7522462 is located in an open
reading frame nearby the kif21b gene. These two
polymorphisms are in linkage disequilibrium with the
each other (R2 > 0.73, based on http://www.broadinstitute.org/mpg/snap/). Therefore, it is unlikely that the assess-
ment of the previously MS-associated SNP in this study
instead of the most recently reported SNP in the kif21b
locus has affected the results.
Genetic variations in both kif21a and kif21b are linked
to several human diseases. Microduplications in the
kif21b locus were identified in two patients with
neurodevelopmental disorders. These two patients
had delayed motor and cognitive development [22]. Kif21a
is a family member of kif21b and has similarities in amino
acid composition, but its expression pattern is different.
Kif21a is expressed throughout neurons and kif21b is
mainly expressed in dendrites. Kif21a is linked to congenital
fibrosis of the extraocular muscles type 1 (CFEOM1), a
disease characterised by absence of motor neurons of the
midbrain and in the superior division of the oculomotor
nerve [23]. Moreover, CFEOM1 with a Marcus Gunn
jaw-winking phenomenon is associated with another
kif21a mutation [24]. Variation in the kif21b locus is
also strongly associated with ankylosing spondylitis
(M. Bechterew) [25] and moderately with ulcerative
colitis [26]. This suggests that kif21b has an additional
function in the immune system, which is beyond the
scope of the current report.
Also other kinesin family members are genetically
associated with human diseases. For example, a variant in
kif5a locus has been linked with the risk to develop
rheumatoid arthritis [27] and is a candidate SNP in MS
Figure 8 Abundant kif21b expression is associated with a shorter disease duration and accelerated progression to sustained
neurological disability. Kif21b expression was correlated with the disease duration of A) Alzheimer patients and B) multiple sclerosis patients. In
both diseases, shorter disease duration was associated with abundant kif21b expression. C) Kif21b expression in MS patients was dichotomised
for the expression above the median and below the median and survival analysis was performed in MS patients. MS patients with kif21b expression
above the median had a significantly shorter time to develop EDSS 6.0, the neurological score for sustained disability. D) The time to develop EDSS 6.0
was stratified according to kif21b MS risk SNP carriership. The rs12122721 [A] SNP is not associated with accelerated time to develop EDSS 6.0.
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http://www.actaneurocomms.org/content/2/1/144[28]. Moreover, kif5a mutations are associated with the
development of hereditary spastic paraplegia (SPG10), a
neurodegenerative disease. At least one mutation in kif5a
decreases both the anterograde and retrograde transport
flux of neurofilaments [29]. Interestingly, we observed a
trend that abundant kif5a is also associated with a
more rapid development of sustained disability in MS
(Additional file 1: Table S6). Additionally, a SNP in
kif1b has been implied as risk SNP for MS [30], but a
subsequent study failed to replicate this finding [20].
Kif21b, a plus end-directed motor kinesin, is produced in
the cell body of the neuron, after which it is transported to
the dendrites, where it is mainly expressed. Kif21b might be
involved in delivering currently unknown cargoes to the
distal regions of dendrites [5]. The physiological function of
kif21b and the mechanisms by which abundant kif21b and
possibly kif5a in neurons contribute to accelerated neuro-
degeneration remain to be determined. Whether abundant
kif21b is the cause or consequence of the accelerated
neurodegeneration needs to be investigated.
Increasingly, it has been recognised that in addition to
white matter lesions, also grey matter pathology in MS
occurs already in early in the disease [2]. One of the
major pathological changes besides demyelination in MSis axonal damage, however relatively little is known
about neuronal damage [31]. It is intriguing to speculate
that kinesins might play a pivotal role in these processes
as they are important for axonal transport and thereby
for neuron integrity, function and survival. Currently, as
far as we are aware of, hardly anything is known about
the expression and distribution of kinesins in MS or AD.
Additionally, we showed that kif21b is also expressed in
activated astrocytes Abundant levels of kif21b expression
have been linked to a poorer prognosis of several forms
of cancers. Increased kif21b expression was observed
in gliomas, brain tumours with a very poor prognosis,
especially the glioblastoma multiforme with a survival
rate of less than a year [32]. Increased kif21b levels were
also observed in three well-characterised astrocytoma cell
lines, KINGS-1, no. 11 and Becher compared with benign
gliomas or healthy brain tissue [33]. This is compar-
able to our findings that kif21b expression increases
during astrocyte activation. High levels of kif21b expres-
sion in neurodegenerative diseases are associated with a
more rapid disease course as we have shown here,
again pointing to an important role of kif21b in
astrocytes. The mechanistic consequences of abundant
kif21b expression and the upregulation of kif21b upon
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http://www.actaneurocomms.org/content/2/1/144activation in astrocytes remain speculative as the function
of kinesins in general and kif21b specifically in astrocytes
is currently unknown.
It is interesting that more severe AD pathology is associ-
ated with enhanced kif21b expression. Reactive astrocytes
are found in regions with amyloid beta deposits in AD path-
ology and these astrocytes have accumulated neuronal
amyloid beta 42 [34]. Astrocytes can be activated when co-
cultured with microglia cells in the presence of amyloid beta
[35]. Additionally, astrocytosis is mainly observed in youn-
ger frontotemporal dementia patients, and this is supportive
for our findings regarding the correlation between kif21b
and GFAP only in the young AD patients [19]. Astrogliosis
is observed in MS white matter lesions, whereas GFAP
expression in grey matter lesions is not increased [36]. This
supports the correlation between GFAP and kif21b in WM
of MS patients, but not in cortical demyelination (Figure 6F
and Additional file 1: Figure S10). The role of astrocytes in
the neurodegenerative component of multiple sclerosis is
also increasingly being recognised [37].
Further research on the cargo transported by kif21b and
the exact function of this kinesin will be important to gain
more insight into the exact mechanisms whereby kif21b
contributes to neurodegeneration. Understanding the
function of kif21b in neurons and astrocytes, may shed
new light on possible mechanisms to therapeutically target
neurodegeneration and malignant brain tumours.
Conclusions
Kif21b is significantly increased in AD patients com-
pared with MS and NDC. In both MS and AD patients,
upregulated kif21b expression was associated with more
severe neuropathology. In MS patients, abundant kif21b
expression was associated with accelerated neurodegen-
eration and a shorter time to develop EDSS 6.0. In AD
patients, increased kif21b was associated with a shorter
disease duration. Kif21b expression was found in neurons
and astrocytes, upon activation of astrocytes, kif21b
significantly increased.
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